secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001193125-25-141795
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell reports LYL314 Phase 1/2 data: 88% ORR, 72% CR in 3L+ LBCL
----------------------------------------------------------------

- In efficacy-evaluable 3L+ patients (N=25), ORR 88% (22/25) with 72% CR; median follow-up 9 months.
- 71% (10/14) of CR patients remained in CR at ≥6 months; no Grade ≥3 CRS; no deaths related to LYL314.
- In 2L patients (N=11), ORR 91% with 64% CR; 100% of CR patients in CR at last assessment (3/3 at ≥6 months).
- Plan to initiate randomized pivotal trial of LYL314 in 2L R/R LBCL by early 2026.
- LyFE manufacturing center expected to support >1,200 CAR T doses annually for clinical and early commercial use.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312525141795/0001193125-25-141795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312525141795/d15114d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-141795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer